Korang SK, Maagaard M, Feinberg JB, Perner A, Gluud C, Jakobsen JC. The effects of adding quinolones to beta-lactam antibiotics for sepsis.
Acta Anaesthesiol Scand 2021;
65:1023-1032. [PMID:
33864250 DOI:
10.1111/aas.13831]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 03/30/2021] [Accepted: 04/09/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND
Sepsis is common, deadly, and a major challenge to treat. Quinolones added to beta-lactam antibiotics are currently recommended as a second-line empiric regimen in sepsis, but the evidence regarding their benefits and harms is unclear.
OBJECTIVE
To assess the benefits and harms of adding quinolones to standard care for sepsis.
DATA SOURCES
We conducted a systematic review of randomized clinical trials with meta-analysis and Trial Sequential Analysis. We searched CENTRAL, MEDLINE, Embase, LILACS, SCI-Expanded, and BIOSIS.
STUDY SELECTION
Randomized clinical trials assessing the effects of adding any quinolone to standard care for children and adults with sepsis.
DATA EXTRACTION AND SYNTHESIS
Two independent reviewers screened studies and extracted data. The certainty of the evidence was assessed by GRADE.
RESULTS
We included three trials randomizing 995 adults. All trials were at overall "high risk of bias." All trials compared a quinolone (moxifloxacin, levofloxacin, or ciprofloxacin) and a beta-lactam antibiotic versus the same beta-lactam antibiotic. We found no evidence of an effect of adding quinolones to beta-lactam antibiotics when assessing all-cause mortality (RR 1.07, 95% CI 0.86 to 1.33; 2 trials; 915 participants; very low certainty of evidence) and serious adverse events (RR 1.00, 95% CI 0.67 to 1.50; 977 participants; two trials; very low certainty of evidence). No trials reported on quality of life.
CONCLUSIONS
The effects of adding quinolones to beta-lactam antibiotics for the treatment of sepsis were unclear for all outcomes. Additional trial data are warranted to support the recommendation of empirical use of quinolones for sepsis.
Collapse